Galantamine Hydrobromide Tablets

GALANTAMINE treats mild to moderate dementia caused by Alzheimer’s disease. It contains ‘Galantamine’, an acetylcholinesterase inhibitor. Galantamine increases acetylcholine (a brain chemical) levels in the central nervous system by blocking the action of the cholinesterase enzyme. This process helps in transmitting nerve signals that play an essential role in memory. GALANTAMINE is not a cure for Alzheimer’s disease but improves memory, thinking awareness and the ability to perform daily functions.

Log in to view price and purchase
SKU: ZP00195 Category: Tags: , ,

Description

GALANTAMINE belongs to a group of medicines called ‘anti-dementia agents’ used to treat mild to moderate dementia caused by Alzheimer’s disease. Alzheimer’s disease is a neurological disorder, which causes dementia (memory loss), and slowly destroys the ability to think, learn, communicate, and handling daily activities. Dementia is a condition associated with impairment in memory, communication and thinking.

GALANTAMINE contains ‘Galantamine’ that belongs to the class of ‘Acetylcholinesterase Inhibitors’. Galantamine blocks the action of the enzyme cholinesterase, an enzyme that breaks down acetylcholine. Acetylcholine is a neurotransmitter or a chemical messenger that transmits the message from one nerve cell to another nerve cell, muscle cell, or gland cell. GALANTAMINE thus increases acetylcholine levels allowing the nerve cells to communicate. It restores the balance of neurotransmitters and thus improves mental function, such as memory and thinking.

Your doctor will decide the dose and duration based on your disease’s severity and response to treatment. Common side effects of GALANTAMINE include nausea, vomiting, diarrhoea, headache, dizziness, drowsiness, shakiness (tremor), weakness, depression, and loss of appetite. These side effects are not familiar to everyone and vary individually. If you notice any side effects that are not manageable, please consult your doctor.

Please tell your doctor if you are allergic to GALANTAMINE or its components. If you are using any prescription and non-prescription medications, let your doctor know before starting GALANTAMINE. Inform your doctor beforehand if you have a history of liver or kidney diseases, heart problems, electrolyte imbalance, stomach ulcer, fits, Parkinson’s disease, breathing disorders, and urination problems. If you had recent surgery on the stomach, intestines or bladder, tell your doctor. If you are pregnant, planning to conceive or a breastfeeding mother, inform your doctor before starting GALANTAMINE. Avoid consuming alcohol along with GALANTAMINE as it can make you dizzy or drowsy.

Uses of GALANTAMINE

Dementia in Alzheimer’s disease. 

Medicinal Benefits

GALANTAMINE treats mild to moderate dementia caused by Alzheimer’s disease. It contains ‘Galantamine’, an acetylcholinesterase inhibitor. Galantamine increases acetylcholine (a brain chemical) levels in the central nervous system by blocking the action of the cholinesterase enzyme. This process helps in transmitting nerve signals that play an essential role in memory. GALANTAMINE is not a cure for Alzheimer’s disease but improves memory, thinking awareness and the ability to perform daily functions.

Directions for Use

Tablet/Capsule: Swallow it as a whole with a glass of water; do not chew, crush or break it. Syrup/Solution: Shake the bottle well before use. Take the prescribed dose by mouth using the measuring cup/dosing syringe/dropper provided by the pack.

Storage

Store in a cool and dry place away from sunlight

Side Effects of GALANTAMINE

  • Nausea
  • Vomiting
  • Dizziness
  • Drowsiness
  • Shakiness (tremor)
  • Weakness
  • Loss of appetite 
  • Diarrhoea
  • Headache
  • Depression

Additional information

Strength

4 mg, 8 mg

Form

Tablets

Pack Size

1*10

Brand

Galantamine Hydrobromide Tablets

Therapeutic Use

Dementia in Alzheimer's disease.

Reviews

There are no reviews yet.

Be the first to review “Galantamine Hydrobromide Tablets”

Your email address will not be published. Required fields are marked *